E-LIB Suche - Ergebnisse für: Keystone, E

1

Considering immuno-autonomics in stratifying successful tre..:

Holman, AJ ; Keystone, E ; Choy, E..
doi:10.1007/s40744-021-00386-w. , 2021

Link: https://doi.org/10.1007/..

2

Pooled analysis of TNF inhibitor biosimilar studies compari..:

Smolen, JS ; Choe, J-Y ; Weinblatt, ME...
https://eprints.whiterose.ac.uk/155539/5/e001096.full.pdf. , 2020

Link: https://eprints.whiteros..

3

Baricitinib contre placebo ou adalimumab chez des patients ..:

Taylor, P ; Keystone, E ; Van Der Heijde, D...
doi:10.1016/s1169-8330(16)30348-9. , 2019

Link: https://doi.org/10.1016/..

4

Clinical outcomes in patients switched from adalimumab to b..:

Tanaka, Y ; Fautrel, B ; Keystone, E...
doi:10.1136/annrheumdis-2018-214529. , 2019

Link: https://doi.org/10.1136/..

5

Nintedanib for Systemic Sclerosis-Associated Interstitial L..:

Distler O ; Highland KB ; Gahlemann M...
info:eu-repo/semantics/altIdentifier/pmid/31112379. , 2019

Link: http://hdl.handle.net/11..

6

Efficacy and safety of switching from adalimumab to baricit..:

Taylor, P ; Keystone, E ; Ortmann, R...
doi:10.3899/jrheum.170256. , 2019

Link: https://doi.org/10.3899/..

7

Efficacy and safety of baricitinib versus placebo and adali..:

Taylor, P ; Krogulec, M ; Dudek, A...
doi:10.1093/rheumatology/kex061.001. , 2019

Link: https://doi.org/10.1093/..

8

Efficacy and safety of switching from adalimumab to baricit..:

Taylor, P ; Keystone, E ; Ortmann, R...
doi:10.1002/art.39977. , 2018

Link: https://doi.org/10.1002/..

9

Efficacy and safety of switching from adalimumab to baricit..:

Weinblatt, M ; Taylor, P ; Keystone, E...
doi:10.1002/art.40700. , 2018

Link: https://doi.org/10.1002/..

10

Microarray pathway analysis comparing baricitinib and adali..:

Emery, P ; Taylor, P ; Weinblatt, M...
doi:10.1002/art.40321. , 2018

Link: https://doi.org/10.1002/..

11

Baricitinib versus placebo or adalimumab in rheumatoid arth..:

Taylor, P ; Keystone, E ; Van der Heijde, D...
doi:10.1056/NEJMoa1608345. , 2017

Link: https://doi.org/10.1056/..

12

Effects of baricitinib on lipid, apolipoprotein, and lipopr..:

Kremer, J ; Genovese, M ; Keystone, E...
doi:10.1002/art.40036. , 2017

Link: https://doi.org/10.1002/..

13

Patient-reported outcomes from a phase 3 study of baricitin..:

Keystone, E ; Taylor, P ; Tanaka, Y...
doi:10.1136/annrheumdis-2017-211259. , 2017

Link: https://doi.org/10.1136/..

14

Efficacy and safety of baricitinib versus placebo and adali..:

Taylor, P ; Krogulec, M ; Dudek, A...
http://dx.doi.org/10.3205/17dgrh156. , 2017

Link: https://doi.org/10.3205/..

15

Efficacy and safety of switching from adalimumab to baricit..:

Taylor, P ; Keystone, E ; Ortmann, R...
http://dx.doi.org/10.3205/17dgrh187. , 2017

Link: https://doi.org/10.3205/..